Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with …
R Murphy, G Chander, M Martinez, C Ward, SR Khan… - BMJ open, 2023 - bmjopen.bmj.com
Introduction Suitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine
neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by …
neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by …
Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with …
R Murphy, G Chander, M Martinez, C Ward… - BMJ …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Suitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine
neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by …
neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by …
Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with …
R Murphy, G Chander, M Martinez, C Ward, SR Khan… - BMJ Open, 2023 - europepmc.org
Introduction Suitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine
neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by …
neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by …
[HTML][HTML] Protocol: Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic …
R Murphy, G Chander, M Martinez, C Ward, SR Khan… - BMJ Open, 2023 - ncbi.nlm.nih.gov
Introduction Suitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine
neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by …
neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by …
Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with …
R Murphy, G Chander, M Martinez, C Ward… - BMJ …, 2023 - search.proquest.com
Introduction Suitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine
neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by …
neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by …
Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with …
R Murphy, G Chander, M Martinez, C Ward, SR Khan… - BMJ Open, 2023 - europepmc.org
Suitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasia
(NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by [68Ga] Ga …
(NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by [68Ga] Ga …